Patents by Inventor An-Hu Li

An-Hu Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PREPARATION OF TEREVALEFIM AND FORMULATIONS THEREOF
    Publication number: 20230372299
    Abstract: The present disclosure provides formulations of an HGF/SF mimetic, terevalefim, as well as methods of preparing and using the formulations. The present disclosure also provides methods of synthesizing terevalefim.
    Type: Application
    Filed: October 13, 2021
    Publication date: November 23, 2023
    Inventors: David Howard Upchurch, An-Hu Li, Weizhong Cai, Marc W. Andersen, Khawla Abdullah Abu-Izza
  • INHIBITORS OF RHO-ASSOCIATED COILED-COIL KINASE
    Publication number: 20230295131
    Abstract: The present disclosure provides compounds of Formula (I); or a pharmaceutically acceptable salt thereof, wherein each of Ring A, Ring B, Ra, Rb, L, R1, R2, m, and n is defined herein, pharmaceutical compositions thereof, methods of inhibiting ROCK1 and/or ROCK2, and methods of treating a ROCK1- and/or ROCK2-mediated disease or disorder.
    Type: Application
    Filed: July 20, 2021
    Publication date: September 21, 2023
    Inventors: An-Hu Li, Shashikanth Ponnala, Satish Kumar Sakilam, Satishkumar Gadhiya, Yao Zong, Dong Sung Lim, Ying Zhang, Dawoon Jung
  • Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors
    Patent number: 11542256
    Abstract: The present invention provides compounds having formula (I): and pharmaceutically acceptable salts thereof, wherein Cy1, Cy2, Cy3, R, R1, R2, R3, A1 and A2 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases in which inhibiting ROCK1, ROCK2, or ROCK1/2 has a therapeutically useful role.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: January 3, 2023
    Assignee: Angion Biomedica Corp.
    Inventors: An-Hu Li, Dibyendu Dana, Dong Sung Lim, Satishkumar Gadhiya, Dawoon Jung, Prakash Narayan, Quaisar Ali, Swarnalatha Paka, Itzhak D. Goldberg
  • PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS
    Publication number: 20220356186
    Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting PERK and for treating related conditions, diseases, and disorders.
    Type: Application
    Filed: August 28, 2020
    Publication date: November 10, 2022
    Inventors: Mark J. Mulvihill, An-Hu Li, Matthew David Surman
  • PERK INHIBITING INDOLINYL COMPOUNDS
    Publication number: 20220348584
    Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting PERK and for treating related conditions, diseases, and disorders.
    Type: Application
    Filed: August 28, 2020
    Publication date: November 3, 2022
    Inventors: Mark J. Mulvihill, An-Hu Li, Matthew David Surman
  • PERK INHIBITING IMIDAZOLOPYRAZINE COMPOUNDS
    Publication number: 20220348583
    Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting PERK and for treating related conditions, diseases, and disorders.
    Type: Application
    Filed: August 28, 2020
    Publication date: November 3, 2022
    Inventors: Mark J. Mulvihill, An-Hu Li, Matthew David Surman
  • PERK INHIBITING COMPOUNDS
    Publication number: 20220332722
    Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting PERK and for treating related conditions, diseases, and disorders.
    Type: Application
    Filed: August 28, 2020
    Publication date: October 20, 2022
    Inventors: Mark J. Mulvihill, An-Hu Li, Matthew David Surman
  • ETHYNYLHETEROCYCLES AS RHO-ASSOCIATED COILED-COIL KINASE (ROCK) INHIBITORS
    Publication number: 20220281841
    Abstract: The present invention provides compounds having formula (I): and pharmaceutically acceptable salts thereof, wherein Cy1, Cy2, Cy3, R, R1, R2, and R3 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases in which inhibiting ROCK1, ROCK2, or ROCK1/2 has a therapeutically useful role.
    Type: Application
    Filed: July 21, 2020
    Publication date: September 8, 2022
    Inventors: An-Hu Li, Satish Kumar Sakilam, Satishkumar Gadhiya, Dong Sung Lim, Yao Zong, Shashikanth Ponnala, Ying Zhang, Dawoon Jung, Lambertus J.W.M. Oehlen
  • Solid forms of (E)-3-[2-(2-thienyl)vinyl]-1H-pyrazole
    Patent number: 11370783
    Abstract: The present disclosure provides solid forms of (E)-3-[2-(2-thienyl)vinyl]-1H-pyrazole, compositions thereof, and methods of making and using the same.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: June 28, 2022
    Assignee: Angion Biomedica Corp.
    Inventors: An-Hu Li, Satish Kumar Sakilam, Dong Sung Lim
  • SOLID FORMS OF (E)-3-[2-(2-THIENYL)VINYL]-1H-PYRAZOLE
    Publication number: 20210078984
    Abstract: The present disclosure provides solid forms of (E)-3-[2-(2-thienyl)vinyl]-1H-pyrazole, compositions thereof, and methods of making and using the same.
    Type: Application
    Filed: December 1, 2020
    Publication date: March 18, 2021
    Inventors: An-Hu Li, Satish Kumar Sakilam, Dong Sung Lim
  • Solid forms of (E)-3-[2-(2-thienyl)vinyl]-1H-pyrazole
    Patent number: 10875849
    Abstract: The present disclosure provides solid forms of (E)-3-[2-(2-thienyl)vinyl]-1H-pyrazole, compositions thereof, and methods of making and using the same.
    Type: Grant
    Filed: July 29, 2020
    Date of Patent: December 29, 2020
    Assignee: ANGION BIOMEDICA CORP.
    Inventors: An-Hu Li, Satish Kumar Sakilam, Dong Sung Lim
  • SOLID FORMS OF (E)-3-[2-(2-THIENYL)VINYL]-1H-PYRAZOLE
    Publication number: 20200369654
    Abstract: The present disclosure provides solid forms of (E)-3-[2-(2-thienyl)vinyl]-1H-pyrazole, compositions thereof, and methods of making and using the same.
    Type: Application
    Filed: July 29, 2020
    Publication date: November 26, 2020
    Inventors: An-Hu Li, Satish Kumar Sakilam, Dong Sung Lim
  • VINYLHETEROCYCLES AS RHO-ASSOCIATED COILED-COIL KINASE (ROCK) INHIBITORS
    Publication number: 20200231576
    Abstract: The present invention provides compounds having formula (I): and pharmaceutically acceptable salts thereof, wherein Cy1, Cy2, Cy3, R, R1, R2, R3, A1 and A2 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases in which inhibiting ROCK1, ROCK2, or ROCK1/2 has a therapeutically useful role.
    Type: Application
    Filed: August 31, 2018
    Publication date: July 23, 2020
    Inventors: An-Hu Li, Dibyendu Dana, Dong Sung Lim, Satishkumar Gadhiya, Dawoon Jung, Prakash Narayan, Quaisar Ali, Latha Paka, Itzhak D. Goldberg
  • Substituted pteridinones for the treatment of cancer
    Patent number: 9351974
    Abstract: Compounds of Formula I, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven or mediated at least in part by RSK. This Abstract is not limiting of the invention.
    Type: Grant
    Filed: November 12, 2012
    Date of Patent: May 31, 2016
    Assignee: OSI Pharmaceuticals, LLC
    Inventors: Meizhong Jin, Mridula Kadalbajoo, An-Hu Li, Mark J. Mulvihill, Kam W. Siu, Arno G. Steinig, Jing Wang
  • Amino pyrimidine anticancer compounds
    Patent number: 9096624
    Abstract: Compounds of Formula 1, as shown below and defined herein: and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers mediated at least in part by FAK.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: August 4, 2015
    Assignee: OSI Pharmaceuticals, LLC
    Inventors: Andrew P. Crew, Dan Sherman, Rama Devi Appari, Xin Chen, Ramesh Chilukuri, Hanqing Dong, Caterina Ferraro, Kenneth Foreman, Ramesh C. Gupta, An-Hu Li, Kathryn M. Stolz, Brian Volk, Robert Zahler
  • DIHYDROPTERIDINONES
    Publication number: 20140315911
    Abstract: Compounds of Formula I, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven or mediated at least in part by RSK. This Abstract is not limiting of the invention.
    Type: Application
    Filed: November 12, 2012
    Publication date: October 23, 2014
    Inventors: Meizhong Jin, Mridula Kadalbajoo, An-Hu Li, Mark J. Mulvihill, Kam W. Siu, Arno G. Steinig, Jing Wang
  • 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
    Patent number: 8735405
    Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: May 27, 2014
    Assignee: OSI Pharmaceuticals, LLC
    Inventors: Lee D. Arnold, Cara Cesario, Heather Coate, Andrew P. Crew, Hanqing Dong, Kenneth Foreman, Ayako Honda, Radoslaw Laufer, An-Hu Li, Kristen Michelle Mulvihill, Mark J. Mulvihill, Anthony I. Nigro, Bijoy Panicker, Arno G. Steinig, Yingchuan Sun, Quinghua Weng, Douglas S. Werner, Michael J. Wyle, Tao Zhang
  • 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
    Patent number: 8653268
    Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: February 18, 2014
    Assignee: OSI Pharmaceuticals, LLC
    Inventors: Mark J. Mulvihill, Radoslaw Laufer, An-Hu Li, Arno G. Steinig
  • Substituted pyrrolo[2,3-b]-pyridines and -pyrazines
    Patent number: 8592448
    Abstract: Compounds of Formula I, as shown below and defined herein: (I) pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers mediated at least in part by Ron and/or Met.
    Type: Grant
    Filed: November 19, 2009
    Date of Patent: November 26, 2013
    Assignee: OSI Pharmaceuticals, LLC
    Inventors: Xin Chen, Melzhong Jin, Andrew Kleinberg, An-Hu Li, Mark J. Mulvihill, Arno G. Steinig, Jing Wang
  • FUSED BICYCLIC KINASE INHIBITORS
    Publication number: 20130253197
    Abstract: Compounds of Formula I, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by at least one of RON, MET or ALK. This Abstract is not limiting of the invention.
    Type: Application
    Filed: April 30, 2013
    Publication date: September 26, 2013
    Applicant: OSI Pharmaceuticals, LLC
    Inventors: Mark J. Mulvihill, Arno G. Steinig, Andrew Philip Crew, Meizhong Jin, Andrew Kleinberg, An-Hu Li, Jing Wang